Dr. Emil Kakkis
CEO of biotechnology company focusing on rare diseases.
Based in CA
🤖
AI Overview
With $100K in lobbying spend across 4 quarterly filings, Dr. Emil Kakkis is an active lobbying client. Their lobbying covers 1 issue area. Active from 2023 to 2024.
$100K
Total Spend
2
Years Active
1
Firms Hired
6
Lobbyists Deployed
1
Issues Lobbied
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2023 | $50K |
| 2024 | $50K |
Issues Lobbied
Lobbying Firms
Lobbyists
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues
- •FDA drug approval process for rare diseases, including increased use of biomarkers in the Accelerated Approval Pathway, clinical trial design and other barriers to approval.
- •FDA regulatory review and approval issues.
Related Analysis
Related Investigations
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Healthcare's $3 Billion Bet
The healthcare industry's massive lobbying investment.
Federal Lobbying Statistics 2025
The definitive stats — $37.7B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.